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Abstract
Background: PepT1, an intestinal epithelial apical di/tripeptide transporter, is normally expressed in the small intestine and
induced in colon during chronic inflammation. This study aimed at investigating PepT1 regulation by butyrate, a short-chain
fatty acid produced by commensal bacteria and accumulated inside inflamed colonocyte.
Results: We found that butyrate treatment of human intestinal epithelial Caco2-BBE cells increased human PepT1 (hPepT1)
promoter activity in a dose- and time-dependent manner, with maximal activity observed in cells treated with 5 mM
butyrate for 24 h. Under this condition, hPepT1 promoter activity, mRNA and protein expression levels were increased as
assessed by luciferase assay, real-time RT-PCR and Western blot, respectively. hPepT1 transport activity was accordingly
increased by ,2.5-fold. Butyrate did not alter hPepT1 mRNA half-life indicating that butyrate acts at the transcriptional level.
Molecular analyses revealed that Cdx2 is the most important transcription factor for butyrate-induced increase of hPepT1
expression and activity in Caco2-BBE cells. Butyrate-activated Cdx2 binding to hPepT1 promoter was confirmed by gel shift
and chromatin immunoprecipitation. Moreover, Caco2-BBE cells overexpressing Cdx2 exhibited greater hPepT1 expression
level than wild-type cells. Finally, treatment of mice with 5 mM butyrate added to drinking water for 24 h increased colonic
PepT1 mRNA and protein expression levels, as well as enhanced PepT1 transport activity in colonic apical membranes
vesicles.
Conclusions: Collectively, our results demonstrate that butyrate increases PepT1 expression and activity in colonic epithelial
cells, which provides a new understanding of PepT1 regulation during chronic inflammation.
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Introduction
Butyrate is a short-chain fatty acid (SCFA) produced in the
colonic lumen by bacterial fermentation of carbohydrates and
dietary fibers [1]. In normal mammals, the colonic lumen contains
100–150 mM total SCFAs [2,3]. The molar ratio of three major
SCFAs acetate, propionate and butyrate (which constitute
approximately 90% of total SCFAs in the lumen varies due to
several factors but is generally about 60:20:20 for acetate:propio-
nate:butyrate [3,4]. In mammals, 95–99% of SCFAs produced in
the colonic lumen are absorbed [4,5]. The pH of colonic lumen is
about 6.2, suggesting that at least 90% of all SCFAs exist under
ionized forms. SCFAs uptake by epithelial cells occurs by simple
diffusion of the unionized forms across cell membranes, whereas
uptake of the ionized form is mediated by apical membrane
monocarboxylic transporter (MCT)-1 [6]. SCFAs are rapidly
metabolized by colonocytes and are the main respiratory fuels in
the intestine; indeed, oxidation of SCFAs supplies 60–70% of the
energy need in isolated colonocytes [7]. Of the three major
SCFAs, butyrate is the main intestinal fuel even in the presence of
competing substrates such as glucose and glutamine [8]. In
addition to its function as the dominant energy source for
colonocytes, butyrate also affects cellular proliferation, differenti-
ation and apoptosis [9,10,11].
Intestinal epithelial cells absorb small dietary peptides by the
action of apical membrane peptide transporters. A cDNA
encoding an apical membrane protein possessing this peptide
transport capability has been cloned from humans and designated
hPepT1 [12,13,14]. PepT1 is primarily expressed in brush border
membranes of enterocytes in the small intestine, in the proximal
tubular cells of the S1 segment of the kidney, and in bile duct
epithelial cells [15,16,17]. Within the small intestine, PepT1 has a
differential pattern of expression. Along the vertical axis, PepT1 is
most abundant at the villous tip and expression decreases towards
the crypt [18]. Along the longitudinal axis, the density of PepT1
increases from duodenum to ileum [19]. PepT1 is also expressed
in immune cells as recently reported [20,21]. PepT1 is generally
not expressed in the esophagus, stomach or normal colon [16,22];
however, hPepT1 expression has been observed in inflamed colon
from patients with inflammatory bowel disease (IBD) [22]
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2476suggesting a link between hPepT1 expression and inflammatory
pathways. Furthermore, hPepT1 expression was found to be
upregulated in the colonic mucosa of patients with short-bowel
syndrome after surgical resection of the proximal small intestine,
which also indicates that hPepT1 expression is induced in colonic
epithelial cells under pathological conditions [23]. In epithelial
cells, butyrate is a potent stimulator of the transcription of
membrane transporters such as the rat Na
+/H
+ exchanger
(NHE3) [24,25] and the human c-epithelial sodium channel [26].
In the present study, we investigated the possibility that butyrate
could induce colonic PepT1 expression and the underlying
molecular mechanisms.
Results
Butyrate is a potent enhancer of hPepT1 promoter
activity
To test the response of the hPepT1 promoter to SCFAs, human
intestinal epithelial Caco2-BBE cells were transfected with a
reporter construct encoding the putative proximal promoter
region of hPepT1 gene (722 bp) previously cloned in our
laboratory ([27]; GeneBank
TM accession number DQ370174).
The transfected cells were treated or not with 5 mM of each
SCFA: acetate, propionate, butyrate, valerate, capronate or
isobutyrate, for 24 h. Luciferase activity relative to hPepT1
promoter activity was then assessed. Our results revealed that of
the six examined SCFAs, butyrate was the most potent enhancer
of hPepT1 promoter activity (Figure 1A). Furthermore, butyrate
increased hPepT1 promoter activity in a dose- and time-
dependent manner, with a maximal increase of ,21-fold observed
after 24 h exposure of cells with 5 mM butyrate (Figure 1B and C).
Treatment with 5 mM butyrate for 24 h was therefore used for
subsequent in vitro studies.
Butyrate increases hPepT1 mRNA and protein expression
We then investigated the effect of butyrate on hPepT1 mRNA
and protein expression levels in Caco2-BBE cells. As examined by
RT-PCR, treatment of cells with 5 mM butyrate for 24 h strongly
increased hPepT1 mRNA level (Figure 2A). In support of this
result, real-time RT-PCR data showed that butyrate induces a
Figure 1. Butyrate increases hPepT1 promoter activity in Caco2-BBE cells. Caco2-BBE cells were transfected with full-length hPepT1
promoter construct and treated with A) 5 mM of the indicated short chain fatty acids for 24 h, B) the indicated concentrations of butyrate for 24 h, or
C) 5 mM of butyrate for the indicated times. Luciferase activity related to hPepT1 promoter activity was measured. Data were normalized by Renilla
activity and expressed as fold increases compared with untreated cells (control). Values represent means6S.E. of three determinations. *P,0.05;
**P,0.005; ***P,0.001 vs control.
doi:10.1371/journal.pone.0002476.g001
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to control cells (Figure 2B). We then examined whether the
increase of hPepT1 mRNA level in butyrate-treated cells is due to
changes in hPepT1 mRNA stability. hPepT1 mRNA expression
levels in Caco2-BBE monolayers treated or not with 5 mM
butyrate for 24 h in the presence or absence of 5 mg/ml
actinomycin D (AcD), a potent transcription inhibitor, were
analyzed by Northern blot. As shown in Figure 2C, the ,2.2-kb
band representing the hPepT1 mRNA was significantly increased
in butyrate-treated cells compared with untreated cells (lane 3 vs
lane 1). However, in the presence of AcD, hPepT1 mRNA was
strongly reduced (lane 2) and the butyrate-induced increase of
hPepT1 mRNA was suppressed (lane 4 vs lane 3). In agreement
with this result, we found by real-time RT-PCR that hPepT1
mRNA levels in AcD-treated cells and AcD+ butyrate-treated cells
were the same (Figure 2D). Together, these results showed that
butyrate did not affect hPepT1 mRNA stability, demonstrating
that it up-regulates hPepT1 at the transcriptional level.
Furthermore, butyrate-treated Caco2-BBE monolayers exhibit-
ed greater hPepT1 protein expression level than untreated cells as
examined by Western blot (Figure 3A). Densitometric analysis of
hPepT1 band intensity revealed that both membrane and cytosol
hPepT1 amounts were significantly increased by ,2.5 fold upon
butyrate treatment (Figure 3B).
Collectively, these data showed that butyrate transcriptionally
up-regulates hPepT1 mRNA expression, resulting in the increase
of hPepT1 protein level.
Butyrate increases hPepT1-mediated dipeptide uptake in
Caco2-BBE monolayers
Since butyrate induces an increase of hPepT1 expression, we
next examined the effect of butyrate on hPepT1 transport activity.
hPepT1-mediated Glycine-Sarcosine uptake was measured in
Caco2-BBE monolayers pre-treated with 5 mM of butyrate for 4,
8, 12 and 24 h. As shown in Figure 4A, addition of butyrate to the
apical compartment significantly increased hPepT1-mediated
Glycine-Sarcosine uptake in a time-dependent manner. The
increase of hPepT1 activity reached a maximal level of ,2.5 fold
compare to the basal level after 24 h treatment. To examine
whether butyrate might affect the peptide transport by modifying
the intrinsic activity of hPepT1, the kinetics of peptide transport in
Caco2-BBE cells were examined in the presence or absence of
butyrate (Figure 4B). The tripeptide KPV (Lys-Pro-Val) was used
for its unique high affinity to PepT1 as previously demonstrated
[21]. Kinetic analysis of the data indicated that butyrate
significantly increased the maximal velocity Vmax (4.2 nmol/
filter/h vs 2.2 nmol/filter/h; P,0.05), but did not modify the
Michaelis-Menten constant Km (408 mM vs 383 mM; non
Figure 2. Butyrate transcriptionally up-regulates hPepT1 expression in Caco2-BBE cells. Caco2-BBE cells were treated with 5 mM butyrate
for 24 h and hPepT1 mRNA levels were assessed by A) semi-quantitative RT-PCR and B) real-time RT-PCR. Values represent means6S.E. of three
determinations. **P,0.005 vs control. To examine butyrate effect on the stability of hPepT1 mRNA, cells were pre-incubated with 5 mg/ml
Actinomycin D (AcD) for 30 min and then treated with butyrate for 24 h. C) Total RNA was analyzed by Northern blot using a probe specific to the
hPepT1 transcript. RNA loading controls were shown as bottom panel. D) hPepT1 mRNA levels were quantified using real-time RT-PCR. Values
expressed as normalized cycling threshold values relative to untreated (0 h) cells represent means6S.E. of three determinations.
doi:10.1371/journal.pone.0002476.g002
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hPepT1 for peptides upon butyrate treatment.
It was previously shown that protein kinase A (PKA) plays a
permissive role in leptin-mediated stimulation of hPepT1 promot-
er activity [27] as well as in NHE3 promoter activation by butyrate
[25]. We therefore investigated if PKA is also involved in butyrate-
mediated up-regulation of hPepT1 promoter and transport
activities. Cells were pre-incubated for 1 h with H89, a specific
PKA inhibitor and then treated or not with butyrate. We found
that 100 mM of H89 almost completely inhibited hPepT1
promoter activity (Figure 5A) and significantly reduced ,85% of
hPepT1 transport activity in butyrate-stimulated Caco2-BBE cells
(Figure 5B). In contrast, H89 did not affect the basal levels of
hPepT1 promoter and transport activities (Figures 5A and B).
Together, these results show that butyrate enhanced hPepT1-
mediated transport events and intracellular signaling pathways like
PKA may be involved.
Butyrate treatment does not modify histone H4
acetylation
Butyrate is a potent histone deacetylase inhibitor and its
suppression of histone deacetylation has been shown to lead to
accumulation of multiacetylated forms of histone especially histone
H4 [28]. Histone acetylation alters the compaction of chromatin,
preventing DNA high order folding and modifying gene
expression. In order to investigate if the acetylation of histone
H4 affects hPepT1 promoter activity, we performed a chromatin
immunoprecipitation analysis (ChiP). Protein-DNA complexes
from butyrate-stimulated or un-stimulated Caco2-BBE cells were
cross-linked and immunoprecipitated with anti-acetyl histone H4
antibody. The precipitates were then PCR-amplified with primers
specific to each of the Cdx2 binding sites (2579, 2262) and the
CREB binding site (+7). As shown in Figure 6, butyrate did not
induce any significant modification of histone H4 acetylation at
hPepT1 promoter regions screened.
Transcription factors Cdx2 and CREB are crucial for
butyrate-induced hPepT1 promoter activity
Since it is known that PKA activates the transcription factor
CREB [29] and we found here that PKA is involved in the
stimulation of hPepT1 promoter activity by butyrate (Figure 5A),
the role of CREB in butyrate-mediated activation of hPepT1
promoter was examined. Figure 7 showed that mutation at
CREB
+7 binding site reduced butyrate-induced activation of
hPepT1 promoter by ,30%, confirming the involvement of PKA.
We have previously shown that the transcription factor Cdx2 plays
an important role in leptin-mediated hPepT1 promoter activation
[27] and Cdx2 is known to be activated by butyrate [30]. Here, we
tested whether Cdx2 binding is required for butyrate-stimulated
hPepT1 promoter activity. Site-directed mutation of individual
Cdx2 binding sites were constructed and transfected into Caco2-
BBE cells. As shown in Figure 7, mutations of Cdx2 binding sites
Figure 3. Butyrate increases hPepT1 protein expression in Caco2-BBE monolayers. A) Caco2-BBE cells grown on filters were treated with
5 mM butyrate for 24 h and membrane and cytosol hPepT1 protein expression was analyzed by Western blot. Expressions of Na
+/K
+ ATPase and
GAPDH were used as loading controls. B) Bar graphs represent the densitometric quantification of hPepT1 blots shown in (A). Values represent
means6S.E. of four blots from independent experiments. **P,0.005.
doi:10.1371/journal.pone.0002476.g003
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hPepT1 promoter activity, whereas mutation at 2564 had no
effect. To confirm the importance of Cdx2 sites located at 2579 or
2262, experiment was repeated using 3 different clones and the
same results were obtained. It is known that the transcription
factor Sp1 has important roles in butyrate-induced activation of
several genes [26] and may be also involved in hPepT1 regulation
[31,32]. hPepT1 promoter contains four Sp1 binding sites located
at 25, 233, 259 and 2199. Point mutations of the Sp1 binding
sites at 259 and 2199 significantly reduced butyrate-induced
increase of hPepT1 promoter activity by ,10% and 5%,
respectively, whereas mutations at 25 and 233 did not affect
Figure 4. Butyrate increases hPepT1-mediated peptides uptake in Caco2-BBE monolayers. Caco2-BBE cells were grown on filters and
apically treated with 5 mM butyrate for the indicated times. Uptake experiments were performed with 20 mM[
14C]Glycine-Sarcosine620 mM
Glycine-Leucine at an apical pH of 6.2 and basolateral pH of 7.4 for 15 min at room temperature, and radioactivity was then measured. Values,
expressed as fold increases compared with untreated cells, represent means6S.E. of three determinations. *P,0.05; **P,0.005 vs untreated cells. B)
Caco2-BBE cells were grown on filters and apically treated with (#) or without (N) 5 mM butyrate for 24 h. Uptake experiments were performed using
20 nM, 120 nM, 10 mM, 100 mm, 400 mm and 1 mM of [
3H]KPV. Results represent means6S.E. of three determinations.
doi:10.1371/journal.pone.0002476.g004
Figure 5. Protein kinase A (PKA) is crucial for butyrate-induced increase of hPepT1 promoter activity in Caco2-BBE cells. A) Caco2-
BBE cells transfected with the full-length hPepT1 promoter construct were pre-treated for 1 h with 40 or 100 mM H89, a specific PKA inhibitor, and
stimulated with 5 mM butyrate for 24 h. Luciferase activity relative to hPepT1 promoter activity was measured. Data were normalized by Renilla
activity and expressed as fold increases compared with control cells. B) Caco2-BBE cells pre-treated or untreated with 100 mM H89 for 1 h were
stimulated with 5 mM butyrate for 24 h. hPepT1-mediated [
14C]Glycine-Sarcosine specific uptake was assessed as described in the Materials and
Methods. Values represent means6S.E. of three determinations. *P,0.05; **P,0.005; ***P,0.001.
doi:10.1371/journal.pone.0002476.g005
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Butyrate was previously implicated in the activation of the
transcription factor AP1 in human colon cancer cells [33]. We
then investigated the role of AP1 in hPepT1 promoter activation
by butyrate. As shown in Figure 7, point mutation at the AP1
2216
binding site did not affect hPepT1 promoter activation by
butyrate.
Together, these results demonstrate that the transcription
factors Cdx2 and CREB have crucial roles in the activation of
hPepT1 promoter by butyrate. Sp1 might also be involved, albeit
to a lesser extent.
Butyrate increases binding of Cdx2 to hPepT1 promoter
To further confirm the importance of Cdx2 in the activation of
hPepT1 promoter, we used electrophoretic mobility shift assays
(EMSA) to characterize their binding to hPepT1 promoter at
Cdx2
2579 (Figure 8A) and Cdx2
2262 (Figure 8B) binding sites.
EMSA were carried out using untreated or butyrate-stimulated
Caco2-BBE cell extracts, together with biotin-labeled double-
stranded oligonucleotides containing the respective consensus
Cdx2 binding sites present in hPepT1 promoter or point-mutated
binding sites. Butyrate increased the binding of Cdx2 transcription
factors to hPepT1 promoter (Figure 8A and B, Lane 2 vs Lane 1).
However, the retardation complexes were not detected in the
presence of labeled oligonucleotides containing point mutations at
Cdx2
2579 and Cdx2
2262 binding sites (Lane 3) or of a 200-fold
molar excess of an unlabeled oligonucleotide competitor (Lane 4),
indicating that the DNA binding of Cdx2 was sequence-specific.
Furthermore, we performed Cdx2 supershift to confirm the
binding of Cdx2 to hPepT1 promoter. As shown in Figure 8C, the
DNA-protein binding complexes were indeed shifted in the
presence of Cdx2 antibody, indicating that Cdx2 bound to
hPepT1 promoter.
Collectively, these results confirm the binding of Cdx2 to
hPepT1 promoter upon butyrate stimulation.
In vivo analysis of the putative Cdx2
2579 and Cdx2
2262
binding sites in untreated and butyrate-treated Caco2-
BBE cells
Since Cdx2 plays a critical role in butyrate-induced hPepT1
expression, we performed a chromatin immunoprecipitation
analysis (ChiP) to confirm that Cdx2 binds to hPepT1 promoter.
Protein-DNA complexes from butyrate-stimulated or un-stimulat-
ed Caco2-BBE cells were cross-linked and immunoprecipitated
with anti-Cdx2 antibodies. The precipitates were then PCR-
amplified with primers specific to each of the Cdx2 binding sites
(2579, 2262). Our results showed that Cdx2 binds to its putative
sites (2579, 2262) in butyrate-stimulated cells but not in un-
stimulated cells (Figure 8D).
These results indicate that Cdx2 may have an in vivo role in
butyrate induction of hPepT1 promoter activity.
The transcription factor Cdx2 regulates hPepT1 protein
expression in Caco2-BBE cells
To confirm the importance of Cdx2 in hPepT1 regulation, we
generated a Caco2-BBE cell line over-expressing V5-tagged Cdx2
(Caco2-BBE/Cdx2) and investigated hPepT1 protein expression
in this cell line. Immunoblot analysis using an anti-V5 antibody
showed a ,42 kDa band representing Cdx2 in Caco2-BBE/
Cdx2, indicating that these cells over-express this transcription
factor (Figure 9A). Under the resting state as well as upon 5 mM
butyrate treatment, Caco2-BBE/Cdx2 have higher hPepT1
protein expression levels than wild-type cells (Caco2-BBE) or cells
transfected with the empty vector (Caco2-BBE/Vector)
(Figure 9B). Caco2-BBE cells were then transiently transfected
with a Cdx2 siRNA (Figure 9C). We found a decrease of hPepT1
expression in cells transfected with Cdx2 siRNA but not in cells
transfected with scramble RNA (Figure 9D, E). This was observed
under both resting state (Figure 9D) and butyrate stimulation
(Figure 9E).
Together, these results indicate that Cdx2 is important to
hPepT1 expression under butyrate stimulation as well as at basal
level.
Butyrate increases hPepT1-mediated inflammation in
Caco2-BBE cells
We previously showed that hPepT1 transports pro-inflamma-
tory bacterial peptides such as fMLP (N-formyl-methionyl-leucyl-
phenylalanine) [34,35]. As we found that butyrate increased
hPepT1 expression and transport activity, we next address if
butyrate may play a role in the increased of hPepT1-mediated
inflammation. Cells pre-treated or not with 5 mM butyrate were
incubated with 1 mM fMLP and degradation of IkB-a was
assessed by Western blot. Figure 10 showed a stronger and faster
Figure 6. Butyrate does not modify histone H4 acetylation in hPepT1 promoter. Soluble chromatin was prepared from Caco2-BBE cells
treated with 5 mM butyrate (+) or vehicle (2) for 24 h. Protein-bound DNA complexes were immunoprecipitated with antibodies against acetyl-
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treated cells, suggesting the effect of butyrate on hPepT1-mediated
inflammation.
Butyrate increases PepT1 expression and transport
activity in mouse colon
To investigate the in vivo effect of butyrate on PepT1 expression,
mice were treated for 24 h with 5 mM butyrate added to the
drinking water and PepT1 expression level in the colonic mucosa
was examined. It has previously shown that the presence of
butyrate in the drinking water did not significantly modify the
volume of water ingested by animals [36,37]. Using real-time RT-
PCR, we found that butyrate treatment induced a significant
increase of PepT1 mRNA expression by ,2-fold compared with
untreated mice (Figure 11A). To confirm this result, PepT1
protein expression level was assessed by Western-blot. PepT1
protein was barely detected in scrapped colonic mucosa from
untreated mice but clearly detected in colonic mucosa from mice
treated with butyrate (Figure 11B). We next examined the effect of
butyrate on PepT1 expression and transport activity in mouse
colonic apical membrane vesicles. The membrane vesicles were
prepared as described in Materials and Methods and analysed by
Western blot for PepT1 expression. We found that butyrate
significantly increased PepT1 expression (Figure 11C). In
agreement, the specific PepT1-mediated transport of [
14C]Gly-
cine-Sarcosine in colonic apical membrane vesicles from butyrate-
treated mice was significantly increased by ,2 times compared
with untreated mice (Figure 11D). These results indicate that
butyrate enhances PepT1 expression and function in mouse colon.
These confirm our in vitro findings showing that butyrate is a
potent PepT1 expression inducer.
Discussion
The human di/tripeptide transporter hPepT1 is not expressed
[22] or barely detected [23] in normal colon. However, its
expression can be induced in inflamed colon as we have previously
shown [22]. Other studies also showed the expression of hPepT1
in colonic epithelial cells from patients with short gut syndrome
[23]. These observations indicate that inflammatory signaling
pathways may regulate the expression of colonic hPepT1.
Here we showed that treatment of human intestinal epithelial
Caco2-BBE cells for 24 h with 5 mM butyrate, an end product in
the breakdown of carbohydrates by anaerobic bacteria, increased
Figure 7. Transcription factors Cdx2 and CREB are crucial for butyrate-induced hPepT1 promoter activity in Caco2-BBE cells. Caco2-
BBE cells were transfected with different constructs of hPepT1 promoter that are point mutated at CREB, Sp1, Cdx2, or AP1 sites. Cells were then
treated with 5 mM butyrate for 24 h and luciferase activity relative to hPepT1 promoter activity was measured. Data were normalized by Renilla
activity and expressed as fold increase in response to butyrate. Values represent means6S.E. of three determinations. *P,0.05; ***P,0.001.
doi:10.1371/journal.pone.0002476.g007
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transporter. However, in normal colon, hPepT1 expression is not
detected although butyrate concentration in the lumen is 10–
15 mM [1,3]. The expression of hPepT1 induced in inflammation
could be explained by a dysfunction of butyrate metabolism in
colonocytes. Indeed, butyrate oxidation in colonocytes from IBD
patients is significantly decreased [38,39]. A decrease of butyrate
oxidation up to 80% was also found in DSS-induced colitis in mice
[40]. This oxidation default can induce an intracellular accumu-
lation of butyrate in colonocytes, which may be responsible for
PepT1 expression. The monocarboxylic transporter (MCT)-1
expressed at the apical membrane of colonic epithelial cells may
also play a major role in butyrate uptake [6]. Therefore, MCT-1
expression level limits the intracellular accumulation of butyrate
[41]. This has previously been confirmed by suppressing the
expression of MCT-1 in vitro, resulting in a marked inhibition of
the ability of butyrate to regulate the expression of several target
genes [41]. It is possible that MCT-1 expression/activity varies
between inflamed and non-inflamed colonocytes, differentially
regulating colonic intracellular concentrations of butyrate, thereby
modulating gene expression.
In the present study, we demonstrated that the transcription
factors Cdx2 and CREB are crucial for the butyrate-induced
increase of hPepT1 expression in Caco2-BBE cells. In adult
mammals, the expression of Cdx2 is largely restricted to the
epithelia throughout the small and large intestines [42]. Cdx2
appears to play critical roles in gut differentiation, proliferation
and neoplasia [43], and it was recently demonstrated that the
gastric mucosa of transgenic Cdx2-overexpressing mice are
morphologically changed to intestinal metaplastic mucosa includ-
ing microvilli and PepT1 expression [43,44]. In agreement with
our finding, it has recently been demonstrated that the intestine-
specific transcription factor Cdx2 is stimulated by butyrate [30].
hPepT1 promoter contains three potential Cdx2 binding sites [27]
and here we showed that two of these located at 2579 and 2262
are crucial for the activation of hPepT1 promoter by butyrate.
These results are in agreement with previous studies that have
reported the crucial role of Cdx2 in hPepT1 basal or leptin-
stimulated activity [27,31]. We have also demonstrated the
importance of the transcription factor CREB in butyrate-mediated
up-regulation of hPepT1 expression. Several studies have shown
the importance of CREB in butyrate-induced gene expression. For
example, short-chain fatty acids regulate tyrosine hydroxylase gene
expression through a cAMP-dependent signaling pathway [45]. In
another report, additional evidence has been provided to show
that exposure to butyrate rapidly activates the MAP kinase
pathway, which is associated with increased CREB phosphoryla-
tion [46]. The phosphorylation of CREB is likely to play a role in
hPepT1 expression since we found that the PKA inhibitor H89
abolished butyrate-mediated increase of hPepT1 transport activ-
ity. However, knocking-out CREB binding site results in a ,30%
decrease of promoter activity. This indicates that PKA can
regulate transcription factors involved in hPepT1 regulation other
than CREB. PKA has been also found to be important for
Figure 8. Butyrate induces Cdx2 binding to hPepT1 promoter in Caco2-BBE cells. A, B, C) Caco2-BBE cells were stimulated or not with
5 mM butyrate for 24 h and EMSA were performed using A) Cdx2
2579 or B) Cdx2
2262 specific probe. Specificity of complexes was assessed using
mutated probe or a 200-fold excess of unlabelled probe. C) Supershift experiments using Cdx2 antibody. D) Soluble chromatin was prepared from
Caco2-BBE cells treated with 5 mM butyrate (+) or vehicle (2) for 24 h. Protein-bound DNA complexes were immunoprecipitated with antibodies
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indicates that butyrate stimulates a PKA-dependent functional
transcriptional regulation of hPepT1 and NHE3 in epithelial cells.
However, it seems that Cdx2 does not play a role in the regulation
NHE3 or the human c-epithelial sodium channel expression
[24,25,26] suggesting the specific role of Cdx2 in regulating
hPepT1 expression/function.
It has been known that butyrate induces an accumulation of
multiacetylated forms of histones [28]. Histone acetylation alters
the chromatin structure at the nucleosomal level, facilitating
changes in DNA transcription. In this study, we were not able to
detect any change in histone H4 acetylation. However we cannot
exclude the possibility that other histones may be hyperacetylated
or histone H4 may be acetylated upstream or downstream of the
areas tested.
Our data demonstrated that butyrate, both in vivo and in vitro,
induced PepT1 expression/activity. It has been reported that
PepT1 transports pro-inflammatory bacterial peptides, such as
muramyl dipeptide (MDP) [47] or N-formyl-methionyl-leucyl-
phenylalanine (fMLP) [20,34,35], which participate in intestinal
inflammation. Butyrate has been shown to exert anti-inflamma-
tory effects in several cell types as well as intestinal biopsy
specimens [48,49]. Here we suggest that intracellular accumula-
tion of butyrate in colonocytes may be involved in intestinal
inflammation via hPepT1 expression and pro-inflammatory
peptide transport. This speculation is supported by i) our results
showing that intestinal epithelial cells pre-treated with butyrate
were more sensitive than un-treated cells to fMLP induces IkB-a
degradation and by ii) publications demonstrating that in vivo
perfusion of fMLP induces PepT1-mediated colonic inflammation
in a short bowel model where PepT1 is expressed in colonic
epithelial cells [50,51]. These findings provide important new
insights to understand the regulation of hPepT1 expression in
intestinal inflammation.
Figure 9. The transcription factor Cdx2 regulates hPepT1 protein expression in Caco2-BBE cells. A) Lysates from wild-type Caco2-BBE
cells, cells overexpressing V5-tagged Cdx2 (Caco2-BBE/Cdx2), or cells transfected with vector alone (Caco2-BBE/Vector) were analyzed by SDS-PAGE
and immunoblot using anti-V5 antibody. B) Wild-type Caco2-BBE cells, Caco2-BBE/Cdx2 or Caco2-BBE/Vector were treated with 5 mM butyrate (+)o r
vehicle (2) for 24 h. Membrane proteins were extracted and hPepT1 expression was assessed by immunoblot. C, D) Caco2-BBE cells were transfected
for 48 h with Cdx2 siRNA and Cdx2 (C) or hPepT1 (D) expression was assessed by immunoblot. E) 24 h after Cdx2 siRNA transfection, Caco2-BBE cells
were treated with 5 mM butyrate for 24 h and hPepT1 expression was assessed by immunoblot. Bar graphs represent blot densitometric
quantification. Values represent means6S.E. of four blots from independent experiments. **P,0.005; ***P,0.001.
doi:10.1371/journal.pone.0002476.g009
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Cell culture and transfection
Caco2-BBE cells were grown in DMEM supplemented with
14 mM NaHCO3, 10% FBS, and penicillin/streptomycin (In-
vitrogen, Grand Island, NY). Caco2-BBE cells stably transfected
with Cdx2-pcDNA3 plasmid [27] were maintained in culture
medium containing 1.2 mg/ml G418 (Invitrogen). Cells were kept
at 37uC in a 5% CO2 atmosphere and 90% humidity, and the
medium was changed each 2 days. Cells were grown on 6-well
plastic plates or on permeable supports (area=1 cm
2; pore size,
0.4 mm; Transwell-Clear polyester membranes from Costar
VWR, Suwanee, GA).
Reagents
SCFAs, Actinomycin D and fMLP were obtained from Sigma-
Aldrich (St. Louis, MO). H89 was purchased from Biosource
(Camarillo, CA).
Animals
Female C57BL/6 mice (8 weeks, 18–22 g, Jackson Laborato-
ries, Bar Harbor, ME) used for this study were group-housed
under a controlled temperature (25uC) and photoperiod (12:12-
hours light-dark cycle), and allowed unrestricted access to standard
diet and tap water. All animal procedures were approved by the
Animal Care Committee of Emory University and were conducted
in accordance to the Guide for the Care of Use of Laboratory Animals
from the US Public Health Service.
Preparation of the reporter constructs
Analysis with the TFSEARCH prediction program (www.cbrc.
jp/) revealed that the cloned promoter region contained multiple
putative biding sites for transcription factors. Site directed





2199,259,233,25 binding sites of the 2634/+89 hPepT1
construct were introduced using the Quick Change XL Site
Directed Mutagenesis Kit (Stratagene, La Jolla, CA) with the
following primers: hPepT1 promoter with mutated CREB
+7, sense
59-CAA CGG GGC CGG GCC TGG AAT TCA GGT CGG
AGG AGT AG-39 and antisense 59-CTA CTC CTC CGA CCT
GAA TTC CAG GCC CGG CCC CGT TG-39; hPepT1
promoter with the first Cdx2
2579 site mutated, sense 59-GAA
ATG TAG AAT CCC CCA GAG ATG CTT TCA AAG GTT-
39 and antisense 59-AAC CTT TGA AAG CAT CTC TGG
GGG ATT CTA CAT TTC-39; hPepT1 promoter with the
second Cdx2
2564 site mutated, sense 59-GGT TGA ATC TCA
AAA TGA AGC CAC ACA CAC ACT CT-59 and antisense 59-
AGA GTG TGT GTG TGG CTT CAT TTT GAG ATT CAA
CC-39; hPepT1 promoter with the third Cdx2
2262 site mutated,
sense 59- AAC CTC CCC TTA GAC TTC TTC GAA ATG
CAC ATT CTG G 39 and antisense 59-CCA GAA TGT GCA
TTT CGA AGA AGT CTA AGG GGA GGT T-39; hPepT1
promoter with the AP1
2216 site mutated, sense 59-AGC CCC
GAC CTC CTG AGT CTG CTG GCC GGG GGG TGG-39
and antisense 59-CCA CCC CCC GGC CAG CAG ACT CAG
GAG GTC GGG GCT-39; hPepT1 promoter with the first
Sp1
2199 site mutated, sense 59-CAG CTG GCC GGG GGG
TTG GGC CTG GGA ATC CGC GTT-39 and antisense 59-
AAC GCG GAT TCC CAG GCC CCA CCC CCC GGC CAG
CTG-39; hPepT1 promoter with the second Sp1
259 site mutated,
sense 59-CTC TGC TCC CCG CAG CAC CGT CCC CCG
GGT GGA GCC-39 and antisense 59-GGC TCC ACC CGG
GGG ACG GTG CTG CGG GGA GCA GAG-39; hPepT1
promoter with the third Sp1
233 site mutated, sense 59-TGG AGC
CGG CGG CCC CTC CTC GCA GAG CTG GGG CTG-39
and antisense 59-CAG CCC CAG CTC TGC GAG GAG GGG
CCG CCG GCT CCA-39; hPepT1 promoter with the fourth
Sp1
25 site mutated, 59-GTA CCT GGG GCA ACG GGG ACG
GGC CTG GAC GTC AGG-39 and antisense 59-CCT GAC
GTC CAG GCC CGT CCC CGT TGC CCC AGG TAC-39.
Figure 10. Butyrate increases hPepT1-mediated inflammation in Caco2-BBE cells. Caco2-BBE cells were treated or not (vehicle) with 5 mM
butyrate for 24 h. Cells were then washed, incubated in serum-free medium overnight and stimulated with 1 mM fMLP for the indicated times. Cell
lysates were analyzed by Western blot using IkB-a antibody. Bar graphs represent the densitometric quantification of IkB-a blots. Values represent
means6S.E. of four blots from independent experiments. **P,0.005.
doi:10.1371/journal.pone.0002476.g010
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cycles of 95uC for 30 sec, 55uC for 2 min and 68uC for 10 min. All
mutants were confirmed by DNA sequencing.
siRNA study
Cdx2 siRNA (59-GCC AUA GAC CUA CAG ACC Utt-39) was
purchased from Ambion (Austin, TX) and transfected into Caco2-
BBE cells using the siPORT NeoFX transfection reagent
(Ambion). 48 hours after transfection, cells were treated with
5 mM butyrate for 24 h, harvested and analyzed by Western blot.
Dual-luciferase reporter assay
Caco2-BBE cells were transfected with 5 ng of a construct
encoding Renilla luciferase (Promega, Madison, WI) and 2 mgo f
the relevant hPepT1 promoter construct using 10 mg/ml lipofectin
(Invitrogen). After stimulation, the resulting luminescence was
measured for 10 s in a luminometer (Luminoskan, Thermal
Labsystems, MA). Each luciferase activity was normalized based on
the control Renilla luciferase activity. Extracts were analyzed in
triplicate,andeachexperimentwasperformedforatleastthreetimes.
Generation of polyclonal antibodies to PepT1
Based on a computerized predictive model for antigenicity and
uniqueness, we designed two synthetic peptides (H2N-
FRHRSKAYPKREHWC-COOH) and H2N-RLEKSNPYFMS-
GANSQKQN), corresponding to residues 248–261 and 689–708
of the deduced hPepT1 protein. The peptides were coupled to
keyhole limpet haemocyanin, and used to raise two antibodies:
(anti-PepT1
248–261; anti-PepT1
689–708) in rabbits via a standard
80-day immunization protocol. The reactivity of the resulting
Figure 11. Butyrate increases PepT1 expression and transport activity in vivo. C57BL/6 mice were given regular water (H2O) or water
containing 5 mM butyrate (H2O+Butyrate) for 24 h. Mice were then sacrificed and colons were removed. A) PepT1 mRNA level was assessed by real-
time RT-PCR (n=10/condition). B) PepT1 expression in colonic mucosa was analyzed by immunoblot (n=10/condition) and representative PepT1
blots from different mice are shown. Expression of villin was shown as loading control. Bar graphs represent densitometric quantification of PepT1
bands. Values represent means6S.E. of four blots from independent experiments. C) Colonic apical membrane vesicles were prepared from H2O2 or
H2O+butyrate-treated mice (n=25/condition) and analyzed for PepT1 expression by Western blot. D) PepT1-mediated specific uptake of [
14C]Glycine-
Sarcosine was measured in the colonic apical membrane vesicles (n=25/condition). Values represent means6S.E. of three determinations.
**P,0.005.
doi:10.1371/journal.pone.0002476.g011
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linked immunosorbent assay (ELISA), and the antibodies were
affinity purified against the synthetic peptide. Anti PepT1
689–708 is
specifically directed to human PepT1 and anti-PepT1
248–261 is
directed to mouse and human PepT1 [20,22].
Protein extraction and Western blot analysis
Total and membrane proteins were extracted as previously
described [27]. Proteins were resolved on 10% polyacrylamide gels
and transferred to PVDF membranes (Bio-Rad, Hercules, CA).
Membranes were probed overnight at 4uC with anti-villin, anti-
GAPDH, anti-IkB-a (Santa Cruz Biotechnology, Inc; Santa Cruz,
CA), anti-V5 (Invitrogen), anti-sodium potassium ATPase (Abcam
Inc; Cambridge, MA) or the appropriate anti-PepT1. After
washing, membranes were further incubated for 1 h at room
temperature with appropriate HRP-conjugated secondary anti-
bodies (Amersham Biosciences, Buckinghamshire, England).
Immunoreactive proteins were detected with the enhanced
chemiluminescence detection system (Amersham Biosciences).
RNA extraction and RT-PCR
Total RNA was extracted using TRIzol reagent (Invitrogen) and
reverse transcribed using Thermoscript
TM RTPCR System
(Invitrogen). The PCR was carried out in a final volume of
50 ml using 2 ml of RT first-strand cDNA product, 1 mM of each
forward and reverse primer, and PCR SuperMix (Invitrogen). The
primers used were: hPepT1 sense 59-CGC CAT GGG AAT GTC
CAA ATC ACA CAG T-39 antisense 59-CAT CTG TTT CTG
TGA ATT GGC CCC-39; b-actin sense 59-GTC ACC CAC
ACT GTG CCC ATC-39 antisense 59-ACG GAG TAC TTG
CGC TCA GGA-39.
Real-time RT-PCR
Real-time PCR with iCycler sequence detection system (Bio-
Rad) was used to assess PepT1 transcripts. Briefly, 50 ng of
reverse-transcribed cDNA was amplified followed by 40 cycles of
95uC for 15 s and 60uC for 1 min, using 10 mM of gene-specific
primers and the iQ SYBR Green Supermix (Biorad). The
GAPDH or 36B4 expression levels were used as house-
keeping genes, and fold-induction was calculated using the Ct
method as follows: DDCT=(CtTarget2Cthousekeeping)treatment2
(CtTarget2Cthousekeeping)nontreatment, and the final data were
derived from 2
2DDCT. The primers used were as follows: hPepT1
sense 59-CGT GCA CGT AGC ACT GTC CAT-39 hPepT1
antisense 59-GGC TTG ATT CCT CCT GTA CCA-39;
hGAPDH sense 59-GTC GGA GTC AAC GGA TTT GG-39
hGAPDH antisense 59-AAG CTT CCC GTT CTC AGC CT-39;
mousePepT1 sense 59-CGT GCA AGT AGCACTGTC CAT-39;
mousePepT1 antisense 59-GGC TTG ATT CCT CCT GTA
CCA-39; mouse36B4 sense 59-TCC AGG CTT TGG GCA TCA-
39 mouse36B4 antisense 59-CTT TAT CAG CTG CAC ATC
ACT CAG A-39.
Electrophoretic mobility shift assay (EMSA)
Cdx2 or CREB-DNA binding activities were analyzed in cellular
extracts prepared in totex buffer (20 mM HEPES/pH7.9, 350 mM
NaCl, 20% glycerol, 1% NP-40, 1 mM MgCl2, 0.5 mM EDTA,
0.1 mM EGTA, protease inhibitors). Samples (5 mg) were incubat-
ed for 15 min at room temperature with a biotin-labeled double-
stranded oligonucleotide (Pierce Rockford, IL) containing
Cdx2
2579,C d x 2
2262 or CREB
+7 binding site. Complexes were
resolved by electrophoresis on 5% TBE gels in 0.56TBE buffer.
Gels were transferred to Biodyne B Pre-cut Modified Nylon
Membranes (Pierce) and complexes were visualized using the
Chemiluminescent Nucleic Acid Detection System (Pierce). The
specificity of the complexes was analyzed by incubation with a 200-
fold excess of unlabeled oligonucleotides as well as a mutated probe.
Supershift assay was performed using 2 mg of Cdx2 antibody
(Zymed Laboratories Inc. laboratories, San Francisco, CA).
hPepT1 mRNA stability assay and Northern blot
For mRNA decay experiments, Caco2-BBE cells pretreated
with 5 mg/ml actinomycin D (AcD) for 1 h to arrest transcription
were incubated with 5 mM butyrate for indicated times. The
hPepT1 mRNA was quantified by real-time RT-PCR as described
above. Northern blot analysis was performed using the North2-
South Complete Biotin Random Prime Labeling and Detection
Kit (Pierce, Rockford, IL) with 20 mg of template total RNAs and
probe generated by RT-PCR with primers as followed: hPepT1-
sense 59-GGA GCC CTG GGA GCC GCC GCC ATG-39 and
hPepT1 antisense 59-TTG TTG CCT GCA GTG TCC ACC
TGG-39.
Chromatin immunoprecipitation assay
Acetyl-histone H4 and Cdx2 chromatin immunoprecipitation
assay (ChIP) was performed using the ChIP assay kit (Upstate Cell
Signaling Solutions, Lake Placid, NY). Briefly, after stimulation cells
were fixed with 1% formaldehyde for 10 min at 37uC (protein to
DNA cross-linking), resuspended in SDS lysis buffer for 10 min on
ice. Cells were then sonicated to shear the DNA into 200–1000 bp
fragments and centrifuged. The supernatant was diluted in ChIP
dilution buffer and pre-cleared with protein A-agarose/salmon
sperm DNA to reduce the nonspecific background. The samples
were then immunoprecipitated with anti-acetyl-histone H4 or anti-
Cdx2 antibodies overnight at 4uC. The complexes were collected in
protein A-agarose/salmon sperm DNA slurry 1 h a 4uC, and then
washed once each with the provided low salt, high salt, and LiCl
wash buffers, and twice in TE buffer (10 mM Tris-HCl, pH 8,
1 mM EDTA). The immunoprecipitated chromatin was eluted
from the protein A using freshly prepared elution buffer (10 mM
NaHCO3, 1% SDS) and the protein-DNA cross-links were reversed
by treatment with 200 mM NaCl at 65uC for 4 h. The DNA was
purified by incubation with proteinase K at 45uC for 1 h, followed
by phenol/chloroform extraction and ethanol precipitation. The
Cdx2 promoter elements in the immunoprecipitates were detected
by PCR using specific primers (Cdx
2579 sense 59-TCT TAA AGA
AAG GAA ATG TAG AAT CC-39 Cdx
2579 antisense 59-TGT
GTG TGT GAA TGA GGA TTG A-39;C d x
2262 sense 59-CCC
ACA GTG GTT TCC AAA GT-39 Cdx
2262 antisense 59-AGC
CAG TCT AAA CGC GGA TT-39). The CREB
+7 promoter
elements were detected using specific primers: CREB
+7 sense 59-
CTC GGG AGC ACG GAC CTC T-39 CREB
+7 antisense 59-
CCT GGC AGG TGC TAC TCC TC-39.
Uptake experiments
Caco2-BBE cells grown on filters for 15 days were treated with
butyrate, washed and incubated with HBSS
+-10 mM HEPES
(pH 7.4) in the basolateral compartment and with HBSS
+-10 mM
MES (pH 6.2) in the apical compartment for 15 min at 37uC.
Apical and basolateral compartments were then incubated for
15 min at room temperature with HBSS
+-10 mM MES (pH 6.2)
containing 20 mM[
14C]Gly-Sar620 mM Gly-Leu and HBSS
+-
10 mM MES (pH 7.2), respectively. Cells were washed twice in
ice-cold PBS, filters were cut, and cell-associated radioactivity was
determined using a b-counter. The results, expressed as specific
uptake of [
14C]Gly-Sar mediated by hPepT1, are calculated as
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The kinetic parameters of peptide transport in Caco2-BBE
monolayers were examined using different doses of [
3H]KPV and
the hPepT1-mediated specific uptakes of [
3H]KPV were per-
formed as described above.
Preparation of mouse colonic apical membrane vesicles
and in vivo uptake experiment
Colonic apical membranes were prepared from mucosal
scraping (n=25 mice/condition) as previously described [52,53].
Briefly, the mucosa was homogenized in a buffer containing
60 mM mannitol, 12 mM Tris-HCl pH 7.4, 10 mM EGTA, and
protease inhibitors. The homogenate was centrifuged at 3,000 g
for 15 min (Step1). The supernatant was incubated with ice-cold
10 mM MgCl2 for 15 min and centrifuged at 27,000 g for 30 min
(Step2). The pellet was resuspended in the homogenization buffer.
Steps 1 and 2 were repeated. The pellet was homogenized in ice-
cold preloading buffer (100 mM KCl, 100 mM mannitol, 20 mM
HEPES/Tris-HCl pH 7.4, protease inhibitors) and centrifuged at
27,000 g for 30 min. The purified colonic apical membrane
vesicles were resuspended in the preloading buffer. In vivo uptake
experiments were performed using a rapid filtration technique
with Millipore filters (HAWP type, 0.45 mm). Uptake of [
14C]Gly-
Sar was performed for 10 s at room temperature using transport
buffer (HBSS
+-10 mM MES pH 6.2, 100 mM mannitol) contain-
ing 300 mg of colonic apical membranes and 20 mM[
14C]Gly-
Sar620 mM Gly-Leu, following by addition of ice-cold stop
solution (2 mM HEPES/Tris pH 7.4, 210 mM KCl) and
filtration. The filters were then washed twice with stop solution
and the radioactivity was determined using a b-counter.
Statistical analysis
All evaluations were performed using SigmaPlot (SPSS,
Chicago, IL) and InStat v3.06 (GraphPad, San Diego, CA)
softwares, with data reported as means6S.E. Multiple groups were
compared by ANOVA, using Tukey’s post-hoc test. P,0.05 was
considered significant.
Author Contributions
Conceived and designed the experiments: DM GD HN. Performed the
experiments: GD YY HN CL. Analyzed the data: SS GD YY HN CL.
Wrote the paper: GD HN.
References
1. Cummings JH (1981) Short chain fatty acids in the human colon. Gut 22:
763–779.
2. Wrong O, Metcalfe-Gibson A, Morrison RB, Ng ST, Howard AV (1965) In
Vivo Dialysis of Faeces as a Method of Stool Analysis. I. Technique and Results
in Normal Subjects. Clin Sci 28: 357–375.
3. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT (1987)
Short chain fatty acids in human large intestine, portal, hepatic and venous
blood. Gut 28: 1221–1227.
4. Cummings JH, Macfarlane GT (1991) The control and consequences of
bacterial fermentation in the human colon. J Appl Bacteriol 70: 443–459.
5. Engelhardt WV, Luciano L, Reale E, Gros G, Rechkemmer G (1989) Transport
of SCFA across the large intestinal epithelium of guinea pig. Acta Vet Scand
Suppl 86: 103–106.
6. Buyse M, Sitaraman SV, Liu X, Bado A, Merlin D (2002) Luminal leptin
enhances CD147/MCT-1-mediated uptake of butyrate in the human intestinal
cell line Caco2-BBE. J Biol Chem 277: 28182–28190.
7. Roediger WE, Millard S (1996) Colonocyte metabolism. Gut 38: 792–793.
8. Clausen MR, Mortensen PB (1994) Kinetic studies on the metabolism of short-
chain fatty acids and glucose by isolated rat colonocytes. Gastroenterology 106:
423–432.
9. McIntyre A, Gibson PR, Young GP (1993) Butyrate production from dietary
fibre and protection against large bowel cancer in a rat model. Gut 34: 386–391.
10. Gamet L, Daviaud D, Denis-Pouxviel C, Remesy C, Murat JC (1992) Effects of
short-chain fatty acids on growth and differentiation of the human colon-cancer
cell line HT29. Int J Cancer 52: 286–289.
11. Ruemmele FM, Schwartz S, Seidman EG, Dionne S, Levy E, et al. (2003)
Butyrate induced Caco-2 cell apoptosis is mediated via the mitochondrial
pathway. Gut 52: 94–100.
12. Liang R, Fei YJ, Prasad PD, Ramamoorthy S, Han H, et al. (1995) Human
intestinal H+/peptide cotransporter. Cloning, functional expression, and
chromosomal localization. J Biol Chem 270: 6456–6463.
13. Fei YJ, Ganapathy V, Leibach FH (1998) Molecular and structural features of
the proton-coupled oligopeptide transporter superfamily. Prog Nucleic Acid Res
Mol Biol 58: 239–261.
14. Adibi SA (1997) The oligopeptide transporter (Pept-1) in human intestine:
biology and function. Gastroenterology 113: 332–340.
15. Sai Y, Tamai I, Sumikawa H, Hayashi K, Nakanishi T, et al. (1996)
Immunolocalization and pharmacological relevance of oligopeptide transporter
PepT1 in intestinal absorption of beta-lactam antibiotics. FEBS Lett 392: 25–29.
16. Ogihara H, Saito H, Shin BC, Terado T, Takenoshita S, et al. (1996) Immuno-
localization of H+/peptide cotransporter in rat digestive tract. Biochem Biophys
Res Commun 220: 848–852.
17. Smith DE, Pavlova A, Berger UV, Hediger MA, Yang T, et al. (1998) Tubular
localization and tissue distribution of peptide transporters in rat kidney. Pharm
Res 15: 1244–1249.
18. Ogihara H, Suzuki T, Nagamachi Y, Inui K, Takata K (1999) Peptide
transporter in the rat small intestine: ultrastructural localization and the effect of
starvation and administration of amino acids. Histochem J 31: 169–
174.
19. Tanaka H, Miyamoto KI, Morita K, Haga H, Segawa H, et al. (1998)
Regulation of the PepT1 peptide transporter in the rat small intestine in
response to 5-fluorouracil-induced injury. Gastroenterology 114: 714–723.
20. Charrier L, Driss A, Yan Y, Nduati V, Klapproth JM, et al. (2006) hPepT1
mediates bacterial tripeptide fMLP uptake in human monocytes. Lab Invest 86:
490–503.
21. Dalmasso G, Charrier-Hisamuddin L, Thu Nguyen HT, Yan Y, Sitaraman S, et
al. (2008) PepT1-mediated tripeptide KPV uptake reduces intestinal inflamma-
tion. Gastroenterology 134: 166–178.
22. Merlin D, Si-Tahar M, Sitaraman SV, Eastburn K, Williams I, et al. (2001)
Colonic epithelial hPepT1 expression occurs in inflammatory bowel disease:
transport of bacterial peptides influences expression of MHC class 1 molecules.
Gastroenterology 120: 1666–1679.
23. Ziegler TR, Fernandez-Estivariz C, Gu LH, Bazargan N, Umeakunne K, et al.
(2002) Distribution of the H+/peptide transporter PepT1 in human intestine:
up-regulated expression in the colonic mucosa of patients with short-bowel
syndrome. Am J Clin Nutr 75: 922–930.
24. Kiela PR, Kuscuoglu N, Midura AJ, Midura-Kiela MT, Larmonier CB, et al.
(2007) Molecular mechanism of rat NHE3 gene promoter regulation by sodium
butyrate. Am J Physiol Cell Physiol 293: C64–74.
25. Kiela PR, Hines ER, Collins JF, Ghishan FK (2001) Regulation of the rat NHE3
gene promoter by sodium butyrate. Am J Physiol Gastrointest Liver Physiol 281:
G947–956.
26. Zeissig S, Fromm A, Mankertz J, Weiske J, Zeitz M, et al. (2007) Butyrate
induces intestinal sodium absorption via Sp3-mediated transcriptional up-
regulation of epithelial sodium channels. Gastroenterology 132: 236–248.
27. Nduati V, Yan Y, Dalmasso G, Driss A, Sitaraman S, et al. (2007) Leptin
transcriptionally enhances peptide transporter (hPepT1) expression and activity
via the cAMP-response element-binding protein and Cdx2 transcription factors.
J Biol Chem 282: 1359–1373.
28. Vidali G, Boffa LC, Bradbury EM, Allfrey VG (1978) Butyrate suppression of
histone deacetylation leads to accumulation of multiacetylated forms of histones
H3 and H4 and increased DNase I sensitivity of the associated DNA sequences.
Proc Natl Acad Sci U S A 75: 2239–2243.
29. Gonzalez GA, Montminy MR (1989) Cyclic AMP stimulates somatostatin gene
transcription by phosphorylation of CREB at serine 133. Cell 59: 675–680.
30. Domon-Dell C, Wang Q, Kim S, Kedinger M, Evers BM, et al. (2002)
Stimulation of the intestinal Cdx2 homeobox gene by butyrate in colon cancer
cells. Gut 50: 525–529.
31. Shimakura J, Terada T, Katsura T, Inui K (2005) Characterization of the
human peptide transporter PEPT1 promoter: Sp1 functions as a basal
transcriptional regulator of human PEPT1. Am J Physiol Gastrointest Liver
Physiol 289: G471–477.
32. Shimakura J, Terada T, Shimada Y, Katsura T, Inui K (2006) The transcription
factor Cdx2 regulates the intestine-specific expression of human peptide
transporter 1 through functional interaction with Sp1. Biochem Pharmacol
71: 1581–1588.
33. Mandal M, Olson DJ, Sharma T, Vadlamudi RK, Kumar R (2001) Butyric acid
induces apoptosis by up-regulating Bax expression via stimulation of the c-Jun
PepT1 Expression and Activity
PLoS ONE | www.plosone.org 13 June 2008 | Volume 3 | Issue 6 | e2476N-terminal kinase/activation protein-1 pathway in human colon cancer cells.
Gastroenterology 120: 71–78.
34. Merlin D, Steel A, Gewirtz AT, Si-Tahar M, Hediger MA, et al. (1998) hPepT1-
mediated epithelial transport of bacteria-derived chemotactic peptides enhances
neutrophil-epithelial interactions. J Clin Invest 102: 2011–2018.
35. Buyse M, Tsocas A, Walker F, Merlin D, Bado A (2002) PepT1-mediated fMLP
transport induces intestinal inflammation in vivo. Am J Physiol Cell Physiol 283:
C1795–1800.
36. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, et al. (2001) Treatment
of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A 98:
9808–9813.
37. Minamiyama M, Katsuno M, Adachi H, Waza M, Sang C, et al. (2004) Sodium
butyrate ameliorates phenotypic expression in a transgenic mouse model of
spinal and bulbar muscular atrophy. Hum Mol Genet 13: 1183–1192.
38. Roediger WE (1980) The colonic epithelium in ulcerative colitis: an energy-
deficiency disease? Lancet 2: 712–715.
39. Den Hond E, Hiele M, Evenepoel P, Peeters M, Ghoos Y, et al. (1998) In vivo
butyrate metabolism and colonic permeability in extensive ulcerative colitis.
Gastroenterology 115: 584–590.
40. Ahmad MS, Krishnan S, Ramakrishna BS, Mathan M, Pulimood AB, et al.
(2000) Butyrate and glucose metabolism by colonocytes in experimental colitis in
mice. Gut 46: 493–499.
41. Daly K, Cuff MA, Fung F, Shirazi-Beechey SP (2005) The importance of colonic
butyrate transport to the regulation of genes associated with colonic tissue
homoeostasis. Biochem Soc Trans 33: 733–735.
42. Silberg DG, Swain GP, Suh ER, Traber PG (2000) Cdx1 and cdx2 expression
during intestinal development. Gastroenterology 119: 961–971.
43. Mutoh H, Satoh K, Kita H, Sakamoto H, Hayakawa H, et al. (2005) Cdx2
specifies the differentiation of morphological as well as functional absorptive
enterocytes of the small intestine. Int J Dev Biol 49: 867–871.
44. Silberg DG, Sullivan J, Kang E, Swain GP, Moffett J, et al. (2002) Cdx2 ectopic
expression induces gastric intestinal metaplasia in transgenic mice. Gastroen-
terology 122: 689–696.
45. DeCastro M, Nankova BB, Shah P, Patel P, Mally PV, et al. (2005) Short chain
fatty acids regulate tyrosine hydroxylase gene expression through a cAMP-
dependent signaling pathway. Brain Res Mol Brain Res 142: 28–38.
46. Shah P, Nankova BB, Parab S, La Gamma EF (2006) Short chain fatty acids
induce TH gene expression via ERK-dependent phosphorylation of CREB
protein. Brain Res 1107: 13–23.
47. Vavricka SR, Musch MW, Chang JE, Nakagawa Y, Phanvijhitsiri K, et al.
(2004) hPepT1 transports muramyl dipeptide, activating NF-kappaB and
stimulating IL-8 secretion in human colonic Caco2/bbe cells. Gastroenterology
127: 1401–1409.
48. Segain JP, Raingeard de la Bletiere D, Bourreille A, Leray V, Gervois N, et al.
(2000) Butyrate inhibits inflammatory responses through NFkappaB inhibition:
implications for Crohn’s disease. Gut 47: 397–403.
49. Tedelind S, Westberg F, Kjerrulf M, Vidal A (2007) Anti-inflammatory
properties of the short-chain fatty acids acetate and propionate: a study with
relevance to inflammatory bowel disease. World J Gastroenterol 13: 2826–2832.
50. Shi B, Song D, Xue H, Li J, Li N, et al. (2006) Abnormal expression of the
peptide transporter PepT1 in the colon of massive bowel resection rat: a
potential route for colonic mucosa damage by transport of fMLP. Dig Dis Sci 51:
2087–2093.
51. Shi B, Song D, Xue H, Li N, Li J (2006) PepT1 mediates colon damage by
transporting fMLP in rats with bowel resection. J Surg Res 136: 38–44.
52. Daniel H, Morse EL, Adibi SA (1991) The high and low affinity transport
systems for dipeptides in kidney brush border membrane respond differently to
alterations in pH gradient and membrane potential. J Biol Chem 266:
19917–19924.
53. Nguyen HT, Charrier-Hisamuddin L, Dalmasso G, Hiol A, Sitaraman S, et al.
(2007) Association of PepT1 with lipid rafts differently modulates its transport
activity in polarized and nonpolarized cells. Am J Physiol Gastrointest Liver
Physiol 293: G1155–1165.
PepT1 Expression and Activity
PLoS ONE | www.plosone.org 14 June 2008 | Volume 3 | Issue 6 | e2476